“This funding will allow us to meet the overwhelming demand from spine surgeons across the country for our highly differentiated products and procedural solutions using the MoRe® superalloy and continue our planned expansion into other important areas, including structural heart disease,” MiRus founder and CEO Jay Yadav, MD, said in a news release.
The Marietta, Ga.-based company touts the performance of its Rhenium alloy products, known as MoRe, compared to traditional alloy medical devices, such that it promises “if the MoRe® rod ever fails, leading to revision surgery, MiRus will pay for the cost of all revision implants,” the release said.
Venture capital firm Mammoth Scientific and practices supporting MiRus led the funding round, MiRus said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
